GAMMA Investing LLC Has $420,000 Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

GAMMA Investing LLC grew its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 4,319.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,359 shares of the company’s stock after acquiring an additional 3,283 shares during the period. GAMMA Investing LLC’s holdings in ARS Pharmaceuticals were worth $420,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of SPRY. Alliancebernstein L.P. raised its stake in shares of ARS Pharmaceuticals by 5,168.4% during the fourth quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company’s stock worth $40,942,000 after buying an additional 3,807,074 shares during the last quarter. Vanguard Group Inc. grew its position in ARS Pharmaceuticals by 3.5% in the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company’s stock valued at $36,555,000 after purchasing an additional 115,656 shares in the last quarter. Alyeska Investment Group L.P. grew its position in shares of ARS Pharmaceuticals by 903.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company’s stock valued at $13,227,000 after acquiring an additional 1,128,724 shares during the period. Geode Capital Management LLC grew its position in shares of ARS Pharmaceuticals by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 1,238,156 shares of the company’s stock valued at $13,066,000 after acquiring an additional 3,351 shares during the period. Finally, Woodline Partners LP lifted its stake in shares of ARS Pharmaceuticals by 13.5% during the 4th quarter. Woodline Partners LP now owns 1,119,283 shares of the company’s stock worth $11,808,000 after buying an additional 133,276 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

ARS Pharmaceuticals Price Performance

SPRY stock opened at $15.91 on Friday. The firm has a market cap of $1.56 billion, a P/E ratio of -99.43 and a beta of 0.84. The company has a quick ratio of 10.74, a current ratio of 11.00 and a debt-to-equity ratio of 0.30. The company’s 50-day moving average price is $14.34 and its two-hundred day moving average price is $12.88. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%. The company had revenue of $7.97 million for the quarter, compared to analyst estimates of $7.48 million. On average, analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Alexander A. Fitzpatrick sold 102,969 shares of the business’s stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total transaction of $1,451,862.90. Following the transaction, the insider now owns 89,613 shares in the company, valued at $1,263,543.30. The trade was a 53.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kathleen D. Scott sold 50,000 shares of the business’s stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total transaction of $705,000.00. Following the transaction, the chief financial officer now owns 7,424 shares in the company, valued at $104,678.40. The trade was a 87.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 322,971 shares of company stock valued at $4,481,888 in the last ninety days. 33.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on SPRY. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Wall Street Zen cut shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Finally, Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.